Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Organ‐on‐a‐Chip: A Preclinical Microfluidic Platform for the Progress of Nanomedicine
Small ( IF 13.0 ) Pub Date : 2020-11-25 , DOI: 10.1002/smll.202003517 Raquel O Rodrigues 1, 2 , Patrícia C Sousa 2 , João Gaspar 2 , Manuel Bañobre-López 3 , Rui Lima 4, 5 , Graça Minas 1
Small ( IF 13.0 ) Pub Date : 2020-11-25 , DOI: 10.1002/smll.202003517 Raquel O Rodrigues 1, 2 , Patrícia C Sousa 2 , João Gaspar 2 , Manuel Bañobre-López 3 , Rui Lima 4, 5 , Graça Minas 1
Affiliation
|
Despite the progress achieved in nanomedicine during the last decade, the translation of new nanotechnology‐based therapeutic systems into clinical applications has been slow, especially due to the lack of robust preclinical tissue culture platforms able to mimic the in vivo conditions found in the human body and to predict the performance and biotoxicity of the developed nanomaterials. Organ‐on‐a‐chip (OoC) platforms are novel microfluidic tools that mimic complex human organ functions at the microscale level. These integrated microfluidic networks, with 3D tissue engineered models, have been shown high potential to reduce the discrepancies between the results derived from preclinical and clinical trials. However, there are many challenges that still need to be addressed, such as the integration of biosensor modules for long‐time monitoring of different physicochemical and biochemical parameters. In this review, recent advances on OoC platforms, particularly on the preclinical validation of nanomaterials designed for cancer, as well as the current challenges and possible future directions for an end‐use perspective are discussed.
中文翻译：
芯片上的器官：纳米医学进展的临床前微流控平台。
尽管在过去十年中纳米医学取得了进展，但基于纳米技术的新型治疗系统向临床应用的转化却进展缓慢，特别是由于缺乏能够模仿人体体内状况的强大的临床前组织培养平台并预测开发的纳米材料的性能和生物毒性。片上器官（OoC）平台是新颖的微流体工具，可在微观水平上模拟复杂的人体器官功能。这些具有3D组织工程模型的集成微流体网络已显示出巨大的潜力，可以减少临床前和临床试验得出的结果之间的差异。但是，仍然有许多挑战需要解决，例如集成生物传感器模块，以长期监测不同的理化和生化参数。在这篇综述中，我们讨论了OoC平台的最新进展，特别是在针对癌症设计的纳米材料的临床前验证方面，以及当前的挑战以及最终用途前景的未来方向。
更新日期：2020-12-22
中文翻译：
芯片上的器官：纳米医学进展的临床前微流控平台。
尽管在过去十年中纳米医学取得了进展，但基于纳米技术的新型治疗系统向临床应用的转化却进展缓慢，特别是由于缺乏能够模仿人体体内状况的强大的临床前组织培养平台并预测开发的纳米材料的性能和生物毒性。片上器官（OoC）平台是新颖的微流体工具，可在微观水平上模拟复杂的人体器官功能。这些具有3D组织工程模型的集成微流体网络已显示出巨大的潜力，可以减少临床前和临床试验得出的结果之间的差异。但是，仍然有许多挑战需要解决，例如集成生物传感器模块，以长期监测不同的理化和生化参数。在这篇综述中，我们讨论了OoC平台的最新进展，特别是在针对癌症设计的纳米材料的临床前验证方面，以及当前的挑战以及最终用途前景的未来方向。
京公网安备 11010802027423号